IN THE CLAIMS

Please cancel claim 16 without prejudice to, or disclaimer of, the subject matter recited therein.

Please amend the following claims:

1. (Amended) An intraoral quickly disintegrating tablet comprising a cyclic GMP phosphodiesterase inhibitor and a saccharide selected from the group consisting of mannitol, xylitol, and erythritol,

wherein the saccharide is present in a ratio of 4 to 30 parts by weight to 1 part by weight of the cyclic GMP phosphodiesterase inhibitor.

13. (Amended) The tablet as claimed in any one of claims 1, 2 and 11, wherein the cyclic GMP phosphodiesterase inhibitor is selected from the group consisting of:

5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one represented the formula (I)



(I)

1,3-dimethyl-6-(2-propoxy-5-methanesulfonamidophenyl)-1,5-

dihydropyrazolo[3,4-d]pyrimidin-4-one represented by the formula (II)



(II)

,

2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline represented by the formula (III)



(III)

,

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indol-1,4-dione represented by the formula (IV)



(IV)

, and

(3S,6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indol-1,4-dione shown by the formula (V)



(V)

or a pharmacologically acceptable salt thereof.

14. (Amended) The tablet as claimed in any one of claims 1, 2 and 11, wherein the cyclic GMP phosphodiesterase inhibitor is a compound represented by the following formula (VI) or a pharmacologically acceptable salt thereof



(VI)

wherein in the formula,

the ring C is an unsaturated 5- or 6-membered ring which may have a hetero atom;

n is 0 or an integer of 1-4;

R^1 is a halogen atom, an optionally substituted lower alkyl

group, an optionally substituted lower alkoxy group, an optionally substituted cycloalkyl group, nitro group, cyano group, a group represented by the formula $-NR^2R^3$, wherein

in the formula, R^2 and R^3 are the same as or different from each other and each is hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, R^2 and R^3 may form a ring together with a nitrogen atom bonded thereto, which ring may further have a substituent,

a group represented by the formula $-O-R^9$, wherein

in the formula, R^9 is hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group,

a group represented by the formula $-S-R^{10}$, wherein

in the formula, R^{10} is hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group,

a group represented by the formula (VII):



wherein in the formula (VII), R^{11} is hydrogen atom, a

lower alkyl group or amino group; and m is 0 or an integer of 1-2,

or an optionally protected carboxyl group, and

when n is 2-4, R^1 may independently have the above-mentioned substituent;

A is hydrogen atom, a halogen atom, a group represented by the formula $-NR^4R^5$, wherein

in the formula, R^4 and R^5 are the same as or different from each other and each is hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or R^4 and R^5 may form a ring together with a nitrogen atom bonded thereto, which ring may further have a substituent,

an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group;

X is a group represented by the formula $-NR^6-$, wherein

in the formula, R^6 is hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group,

or a group represented by the formula -N=;

Y is a group represented by -CO- or a group represented by the formula -C(B)=, wherein

in the formula, B is hydrogen atom, a halogen atom, a formula represented by the formula $-NR^7R^8$, wherein in the formula, R^7 and R^8 may be the same as or different from each other and each is hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, R^7 and R^8 may form a ring together with a nitrogen atom bonded thereto, which ring may further have a substituent, a group represented by the formula $-O-R^{12}$, wherein in the formula, R^{12} is hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, a group represented by the formula $-S-R^{13}$, wherein in the formula, R^{13} is hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group; and

the formula (VIII) ----- means a double or single bond, provided that when the ring C is a benzene ring, the case where n is 0 is excluded.

15. (Amended) The tablet as claimed in claim 14, wherein

the compound represented by the formula (VI) is selected from the group consisting of:

4-(3-chloro-4-methoxybenzyl)amino-6-cyano-1-(4-hydroxypiperidino)phthalazine hydrochloride represented by the formula (IX)



(IX)

4-(3-chloro-4-methoxyphenethyl)amino-6-cyano-1-(4-hydroxypiperidino)phthalazine hydrochloride represented by the formula (X)



(X)

4-[(3-chloro-4-methoxybenzyl)amino]-1-(2-hydroxy-7-azaspiro[3,5]non-7-yl)-6-phthalazine carbonitrile hydrochloride represented by the formula (XI)



(XI)

1-(2-hydroxy-7-azaspiro[3,5]non-7-yl)-4-[(4-methoxy-3-methylbenzyl)amino]-6-phthalazine carbonitrile hydrochloride represented by the formula (XII)



.HCl (XII)

1-[4-fluoro-4-(hydroxymethyl)piperidino]-4-[(4-methoxy-3-methylbenzyl)amino]-6-phthalazine carbonitrile hydrochloride represented by the formula (XIII)



.HCl (XIII)

4-[(3-chloro-4-methoxyphenethyl)amino]-1-(2-hydroxy-7-azaspiro[3,5]non-7-yl)-6-phthalazine carbonitrile hydrochloride shown by the formula (XIV)



.HCl (XIV)

, and

4-[(3-chloro-4-methoxybenzyl)amino]-1-(3-oxo-2-oxa-8-azaspiro[4,5]decen-8-yl)-6-phthalazine carbonitrile represented by the formula (XV)



(XV)

17. (Amended) The method for manufacturing as claimed in any one of claims 3 and 4, wherein the cyclic GMP phosphodiesterase inhibitor is selected from the group consisting of:

5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one represented by the formula (I), and

a compound represented by the formula (VI),

or pharmacologically acceptable salts thereof.

Attached hereto is a marked up version showing changes made to the application by this Reply.